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http:WHAT THIS PAPER ADDS
This is the largest study of outcomes after lower limb bypass in patients with end-stage renal failure. Cumulative
mortality was 49.6% at 2 years. Freedom from major adverse limb events was 77.4%, and freedom from
amputation was 85.0%. Additionally, a multi-regression analysis revealed that an ejection fraction <40%, a
serum albumin level <3.0 g/dL, and non-ambulatory status were independent predictors of a poor outcome.Objective: To assess and risk-stratify the medium-term clinical outcomes after infrainguinal bypass grafting (IBG)
to treat critical limb ischaemia (CLI) in patients with end-stage renal disease.
Methods: This was a retrospective single-centre study. Between April 2007 and March 2011, 112 limbs from 89
patients were studied. In particular, amputation-free survival (AFS), 30 day mortality, freedom from major
adverse limb events (MALE), limb salvage, and overall survival were examined. The aim was to identify outcome
predictors.
Results: Eight patients (9%) died within 30 days of IBG. The only positive predictor of 30-day mortality was an
ejection fraction (EF) < 40% (hazard ratio [HR] 5.57, 95% conﬁdence interval [CI] 1.16e26.83; p ¼ .03). The mean
follow-up duration was 14 months. The 1- and 2-year AFS rates were 64% and 43%, respectively, and the rates of
freedom from MALE were 81% and 77%, respectively. In addition, the 1- and 2-year limb salvage rates were 89%
and 85%, and the survival rates were 68% and 50%, respectively. Non-ambulatory status was negatively
associated with AFS (HR 3.04, 95% CI 1.59e5.82; p < .01), freedom from MALE (HR 4.98, 95% CI 1.91e12.96;
p < .01), and limb salvage (HR 5.18, 95% CI 1.47e18.30; p ¼ .01). The other negative predictors of overall
survival were a serum albumin level <3.0 g/dL (HR 2.26, 95% CI 1.12e4.58; p ¼ .02) and an EF <40% (HR 2.24,
95% CI 1.05e4.79; p ¼ .04).
Conclusion: Patients with CLI on dialysis enjoyed satisfactory freedom from MALE and limb salvage, but survival
and AFS were signiﬁcantly less than reported for IBG in patients with CLI who did not receive dialysis. In addition,
patients with an EF <40%, lower serum albumin (<3.0 g/dL), or non-ambulatory status experienced particularly
poor clinical outcomes after IBG.
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Critical limb ischaemia (CLI) is a limb threatening condition
that requires revascularisation to relieve ischaemic pain,
heal ischaemic ulcers, prevent limb loss, and preserve
ambulatory status and quality of life. Patients with CLI who
do not undergo arterial revascularisation have mortality
and amputation rates as high as 54% and 46%, respec-
tively, after 12 months.1 In contrast, patients with CLI who
undergo successful revascularisation survive longer and
have an improved quality of life compared with patients
who only receive medical treatment or who undergorresponding author.
il address: komori@med.nagoya-u.ac.jp (K. Komori).
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//dx.doi.org/10.1016/j.ejvs.2014.08.022primary amputation.2 Surgical bypass with an autogenous
vein represents the gold standard for CLI treatment, with
numerous reports documenting graft and limb related
outcomes. Recently, the application of endovascular ther-
apy (EVT) to treat CLI has increased, and this technique is
particularly attractive for patients at increased risk for
surgery. In fact, certain studies have advocated the
preferential use of EVT as an initial approach in CLI.3,4
However, the ﬁrst line treatment for revascularisation in
CLI remains controversial. The Trans-Atlantic Inter-Society
Consensus (TASC) recommends that the proﬁle and extent
of arterial lesions should be used to select EVT or bypass
surgery, whereas the ‘Bypass versus Angioplasty in Severe
Ischaemia of the Leg’ (BASIL) trial group suggests that life
expectancy >2 years and good vein quality are better
served by selecting autogenous vein bypass surgery as the
initial treatment.2,5
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end-stage renal disease (ESRD) has been associated with
poor medium and long-term survival.6 Therefore, careful
selection of patients for surgery is essential. However, a few
small to medium sized studies have addressed infrainguinal
bypass grafting (IBG) in patients with ESRD. Moreover, little
information is available regarding the predictors of short
and medium-term outcomes after IBG in patients receiving
haemodialysis.
The aims of this study were to assess, at a single insti-
tution in Japan, the short and medium-term outcomes of
IBG in patients with ESRD and to identify the preoperative
factors that may be predictive of 30 day mortality, ampu-
tation free survival (AFS), freedom from major adverse limb
events (MALE), limb salvage, and survival.
METHODS
Study design
This clinical investigation was undertaken to compare the
pre-operative medical risk factors with the outcomes of
consecutive patients with ESRD on haemodialysis who had
undergone de novo IBG to treat CLI at the Kokura Memorial
Hospital. Approval for this project was obtained from the
hospital’s institutional review board. A retrospective
assessment was performed for each patient, and the data
were statistically analysed to identify prognostic factors of
short and medium-term clinical outcomes.
Patients
Consecutive patients with critically ischaemic limbs and
peripheral arterial disease who had undergone de novo
infrainguinal revascularisation at the authors’ hospital from
April 2007 to March 2011 were analysed retrospectively. All
of the patients were symptomatic (Fontaine classiﬁcation III
[rest pain] or IV [tissue loss/gangrene] and Rutherford cat-
egories 4e6), with threatened limb loss. We excluded pa-
tients with CLI that was attributable to acute arterial
occlusion or to either non-atherosclerotic or inﬂammatory
disease.
During the study period, IBG was performed in 162 pa-
tients (198 limbs), EVT in 221 (260 limbs), and primary
amputation in 21 patients (21 limbs). Among these patients,
186 (229 limbs) with ESRD presented with CLI. The patients’
laboratory tests, cardiovascular function (peripheral angi-
ography, electrocardiography, coronary angiography, and
echocardiography), respiratory function, and other param-
eters were examined routinely. Each case was also dis-
cussed with interventional cardiologists, and the decision
was made over which procedure, whether EVT or bypass,
would be the ﬁrst line treatment depending on general
condition and lower limb severity. Primary amputation was
performed in patients with severe dementia or long-term
bedridden status due to neurogenic deﬁcits, extensive
infection above the ankle, or refusal of revascularisation.
Ultimately, of the 186 patients, 117 (140 limbs) underwent
EVT and nine patients (9 limbs) underwent primary
amputation.IBG was performed in 89 dialysis dependent patients
(112 limbs). Of the patients who underwent IBG, 29 (32
limbs) experienced the endovascular-ﬁrst approach. Of
these, six patients (six limbs) underwent IBG after failed
angioplasty, and the others were cases in which angio-
graphic technical success (one straight line to the foot) was
obtained, but wound healing was not, so IBG was then
performed. The cases of these patients were reviewed and
clariﬁcation of their clinical outcomes was attempted.
Revascularisation procedure and follow-up
All of the infrainguinal bypasses in the patients with CLI
were performed using vein grafts. The distal anastomotic
site was chosen based on the optimal run-off vessel to the
diseased toe. Proximal anastomoses were performed with
6-0 polypropylene sutures, and distal anastomoses were
performed with 7-0 or 8-0 polypropylene sutures. For
distal anastomoses, the non-dissection method with
pneumatic tourniquets to control blood ﬂow was used.
The greater saphenous vein was used as a ﬁrst choice
conduit if its diameter was >2 mm, as determined pre-
operatively by a duplex scan in the standing position. If
this vein was not accessible, the lesser saphenous vein or
an arm vein was used. If the single saphenous vein was too
short, a spliced vein graft was created with 7-0 poly-
propylene sutures. Upon completion of the anastomoses,
angiography was performed to check for graft stenosis and
anastomotic site problems. Moreover, graft ﬂow was
assessed by ultrasonography using a linear transducer. The
measurements were obtained using a transit time ﬂow-
meter (300-Series Flowmeter; Transonic Systems Inc., NY,
USA). More speciﬁcally, a pre-calibrated probe of a size
that ﬁtted the graft (from 3e4 mm) was placed around the
vein graft. This procedure was performed after the
completion of IBG. Additionally, heparin was infused for 24
hours, and prostaglandin E1 was infused for several days
postoperatively. Antiplatelet drugs were also administered
to every patient.
Routine follow up consisted of post-operative visits every
month for 3 months, followed by visits at 3 month intervals
for 2 years and at 6 month intervals thereafter. Routine
surveillance included ankle-brachial index (ABI), skin
perfusion pressure (SPP), and duplex ultrasound (US) mea-
surements. Duplex scanning of the graft was the primary
method for detecting occult graft lesions. A focal increase in
graft velocity (peak systolic velocity >300 cm/s) was
considered signiﬁcant and was followed by arteriography
and revision when appropriate.
Deﬁnitions
CLI was deﬁned as tissue loss/gangrene and rest pain lasting
>2 weeks, in accordance with TASC guidelines.2 CLI was
associated with ankle pressure (<50 mmHg for rest pain;
<70 mmHg for tissue loss) or toe pressure (<30 mmHg for
rest pain; <50 mmHg for tissue loss). When these mea-
surements could not be obtained because of intractable
rest pain or a non-compressible artery secondary to severe
Table 1. Patient demographic data.
n %
Patient status
Age (y) 70  10
Sex, male 67 75
Non-ambulatory 31 35
Albumin (g/dL) 3.4  0.5
Albumin <3.0 g/dL 19 21
Haematocrit (%) 31.6  5.3
Risk factors
Hypertension 71 80
Hyperlipidaemia 13 15
Diabetes mellitus 57 64
Cardiovascular disease 61 69
Ejection fraction 56.8  14.6 17
EF <40% 15 34
Cerebrovascular disease 30 89
Lower limb status (per limb)
Fontaine classiﬁcation IV 100 89
ABI before bypass 0.54  0.35
SPP before bypass 22  12
Medication
Cilostazol 24 27
Aspirin 69 78
Warfarin 22 25
Statin 11 12
b-blocker 17 19
Note. ABI ¼ ankle-brachial index; SPP ¼ skin perfusion pressure.
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was deﬁned as indicative of a critically ischaemic limb.7
Coronary artery disease (CAD) was deﬁned as a history
of any revascularisation of the coronary arteries. Cere-
brovascular disease (CVD) was deﬁned as a history of
stroke, cerebral haemorrhage, and/or any revascularisation
of the carotid arteries. Diabetes mellitus (DM) was diag-
nosed in patients who were taking hypoglycaemic drugs or
self-injected insulin. Ambulatory status was deﬁned as the
patient’s functional status immediately prior to surgery.
Non-ambulatory status was deﬁned as wheelchair bound
or bedridden status, and included patients who were able
to walk with a cane or by themselves pre-operatively but
who later could not walk owing to ischaemic toe or foot
lesions. Major amputation included amputation above the
ankle. With regard to non-ambulatory status, this was a
retrospective study based on the database or medical re-
cords, which were occasionally unclear regarding what
caused the patients’ non-ambulatory status. Certain pa-
tients might have suffered from CLI in the diseased limb for
a long time or had undergone prior contralateral ampu-
tation and were not able to walk by themselves at surgery.
Others might have been non-ambulatory because of
co-morbidities, such as stroke, spinal disease, and so on.
IBG for patients with bedridden status due to neurogenic
deﬁcits was not performed. Such patients usually received
primary amputation. However, for some of the wheelchair
bound patients, the preservation of the foot was less
difﬁcult; thereafter, salvage of the diseased limb was
attempted.
Survival data were obtained from the outpatient clinic
follow-up contacts.
Clinical end points
The end points of the present study were peri-operative
death (30-day mortality); AFS; and freedom from MALE,
which were deﬁned as an above ankle amputation of the
index limb or major re-intervention. These outcomes com-
bined life and limb prognoses. Overall survival and the limb
salvage rate were also assessed.8
Statistical analysis
Values are expressed as mean  SD. The baseline charac-
teristics of the patients were compared using the t test or
the ManneWhitney test, where appropriate, for continuous
data, and the chi-square test or Fisher’s exact test was
utilised for categorical data. A logistic regression model was
used for multivariate analysis to determine the factors
predictive of 30-day mortality. Additionally, cumulative
event rates were estimated using KaplaneMeier survival
curves, and Cox multivariate regression analysis was used to
determine the predictors of medium-term clinical outcomes
(AFS, freedom from MALE, limb salvage, and survival). Any
covariates with p-values <.10 in the univariate analysis
were assessed by multivariate analysis. A p-value <.05 was
considered signiﬁcant. The statistical analyses were per-
formed using SPSS version 21 (IBM, Armonk, NY, USA).RESULTS
Patient characteristics
The overall characteristics of the dialysis dependent pa-
tients with CLI who underwent de novo IBG are shown in
Table 1. The rate of non-ambulatory patients was 35%. In
total, 57 (64%) patients had DM, 61 (69%) had CAD, and 30
(34%) had CVD. Among the group, 89% were Fontaine class
IV. Moreover, the mean preoperative ABI and SPP were
0.54  0.35 and 22  12 mmHg, respectively.Surgical procedures
Table 2 summarises the details of the bypass surgery.
Concerning revascularisation in aortoiliac lesions, EVT was
performed in 16 patients (18 limbs), whereas bypass sur-
gery was not performed.
The inﬂow vessel was the common femoral artery in 37
limbs, the superﬁcial femoral artery in 14 limbs, the above
knee (AK) popliteal artery in 22 limbs, and the below knee
(BK) popliteal artery in 39 limbs. The outﬂow target vessel
was the popliteal artery in 14 limbs (AK ¼ 9; BK ¼ 5), the
anterior tibial in 41, the posterior tibial in 18, the peroneal
in two, the dorsalis pedis in 32, and the plantar artery in ﬁve
limbs. Many of the cases had poor runoff, and the mean
value of the Rutherford runoff score was 8.4.9
A non-reversed vein graft was used in 72 limbs, a reversed
vein graft in 21, an in situ vein graft in two, and a spliced vein
graft in 17 limbs. The ABI and SPP were usually measured
nearly 1 week after bypass grafting. The post-operative ABI
and SPP were 0.99  0.21 and 54  20 mmHg, respectively.
Table 2. Operative details.
n %
Conduit Non-reversed vein graft 72 64
Reversed vein graft 21 19
In situ vein graft 2 2
Spliced vein graft 17 15
Inﬂow Common femoral artery 37 33
Superﬁcial femoral artery 14 13
Popliteal artery (AK) 22 20
Popliteal artery (BK) 39 35
Outﬂow Popliteal artery (AK) 9 8
Popliteal artery (BK) 5 4
Anterior tibial artery 41 37
Posterior tibial artery 18 16
Peroneal artery 2 2
Dorsal pedis artery 32 29
Plantar artery 5 5
Operation time (min) 277  72
Blood loss (mL) 198  237
Mean graft ﬂow (mL/min) 29.2  23.5
Note. AK ¼ above knee; BK ¼ below knee.
Table 4. Post-operative complications.
n %
Heart failure 4 4
Myocardial infarction/angina 3 3
Pneumonia/respiratory failure 3 3
Stroke 2 2
Sepsis 4 4
Ischaemic colitis/bowel infarction 4 4
Graft infection 5 5
Graft occlusion (<24 h) 1 1
Graft occlusion (<30 d) 6 5
Wound infection 6 5
Haematoma/bleeding 2 2
Gastro-intestinal bleeding 3 3
Other 10 8
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The cases with 30-day mortality are listed in Table 3. Eight
(9%) patients died within 30 days of de novo bypass grafting,
two of whom died suddenly owing to severe aortic valve
stenosis. Table 4 summarises the details of the 30 day post-
operative complications, including those associated with six
grafts, two of which became infected, one of which devel-
oped bleeding from the anastomosis (<24 hours), and one of
which became occluded. Acute coronary syndrome occurred
in three (3%) cases, and stroke occurred in two (2%).
After the univariate analysis, an ejection fraction (EF)
<40% and a serum albumin level (Alb) <3.0 g/dL were
identiﬁed as pre-operative factors with a p-value <.10.
Thereafter, a logistic regression analysis of these factors was
performed. The results of the multivariate analysis showed
that an EF <40% was an independent risk factor for 30-day
mortality (hazard ratio [HR] 5.57, 95% conﬁdence interval
[CI] 1.16e26.83; p ¼ .03).
Medium-term outcomes
The mean follow up duration was 418  345 days. During
this period, several re-interventions were performed.Table 3. 30-day mortality cases.
Patient Age (y)/sex Fontaine classiﬁcation Co-morbidities
1 68/M IV CAD, CVD, AS
2 57/M IV CAD, PMI
3 75/M IV CAD, PMI
4 65/F IV DM, CAD, CVD, P
5 66/M IV CAD, AS, CVD
6 79/F IV CAD, CVD
7 75/F IV DM
8 73/M IV CAD, CVD
Note. M ¼ male; F ¼ female; CAD ¼ coronary artery disease; CVD ¼ ca
insertion; DM ¼ diabetes mellitus; PA ¼ popliteal artery; AK ¼ ab
CFA ¼ common femoral artery; ATA ¼ anterior tibial artery; PTA ¼ p
failure.Endovascular treatment was administered for vein grafts in
ﬁve cases, for crural arteries in two, and for femoropopliteal
arteries in two. Patch plasty of vein grafts was performed in
seven cases, and bypasses were re-performed in three.
The primary patency was 66% and 58% at 1 and 2 years,
respectively, and the assisted primary patency was 79% and
77% at 1 and 2 years, respectively. Additionally, the sec-
ondary patency was 81% and 81% at 1 and 2 years,
respectively.
AFS is shown in Fig. 1A, with values of 64% and 43% at 1
and 2 years, respectively. The results of the multivariate Cox
proportional hazard regression analysis of AFS are shown in
Supplementary Table S1. Non-ambulatory status (HR 3.04,
95% CI 1.59e5.82; p < .01) was negatively associated with
AFS.
The rates of freedom from MALE were 81% and 77% at 1
and 2 years, respectively (Fig. 1B; Supplementary Table S2).
The only predictor of MALE was non-ambulatory status (HR
4.98, 95% CI 1.91e12.96; p < .01).
The overall limb salvage rates were 89% and 85% at 1 and
2 years, respectively (Fig. 1C). Twelve legs were amputated,
of which ﬁve legs (AK ¼ 1; BK ¼ 4) were amputated owing
to widespread infection, although their bypass grafts were
patent. The single regression analysis results for limb
salvage were Rutherford category 6 and non-ambulatory
status. Multivariate analysis of limb salvage conﬁrmed
non-ambulatory status as a predictor (HR 5.18, 95% CI
1.47e18.30; p ¼ .01).Inﬂow Outﬂow Survival days Cause of death
PA (AK) ATA 11 AS, VF
SFA ATA 5 Respiratory failure
PA (BK) PTA 11 Sepsis
MI CFA PA (AK) 9 Unknown
PA (AK) PTA 16 AS
CFA PA (AK) 3 Bowel infarction
PA (BK) ATA 14 Stroke
PA (BK) DPA 17 Acute pancreatitis
rdiovascular disease; AS ¼ aortic valve stenosis; PMI ¼ pacemaker
ove knee; SFA ¼ superﬁcial femoral artery; BK ¼ below knee;
osterior tibial artery; DPA ¼ dorsal pedis artery; VF ¼ ventricular
Figure 1. (A) Amputation free survival (AFS) after infrainguinal bypass grafting for 89 patients with critical limb ischaemia (CLI). AFS was
64  5%, 43  6%, and 33  8% at 1, 2, and 3 years, respectively. (B) Freedom from major adverse limb events (MALE) after infrainguinal
bypass grafting for 112 cases of CLI. Overall freedom from MALE was 81  4%, 77  5%, and 74  2% at 1, 2, and 3 years, respectively. (C)
Limb salvage rate (LS) after infrainguinal bypass grafting for 112 patients with CLI. LS was 89  4%, 85  4%, and 33  8% at 1, 2, and 3
years, respectively. (D) Overall survival (OS) rate after infrainguinal bypass grafting for 89 cases of CLI. OS was 68  5%, 50  7%, and
45  8% at 1, 2, and 3 years, respectively.
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respectively (Fig. 1D). In total, 38 patients died during the
follow up period (3e1,110 days) from the following causes:
respiratory disease (n ¼ 8), cardiovascular disease (n ¼ 6),
sepsis (n ¼ 4), bowel ischaemia (n ¼ 3), stroke (n ¼ 2),
other causes (n ¼ 6), and unknown causes (n ¼ 9). The
results of the single regression analysis for survival were
Fontaine classiﬁcation IV, Alb <3.0 g/dL, an EF <40%, and
non-ambulatory status with a p-value <.10. Multivariate
analysis of survival conﬁrmed Alb <3.0 g/dL (HR 2.26, 95%
CI 1.12e4.58; p ¼ .02), an EF <40% (HR 2.24, 95% CI 1.05e
4.79; p ¼ .04), and non-ambulatory status (HR 2.35; 95% CI
1.19e4.64; p ¼ .01) as negative predictors.
These clinical outcomes and their predictors are sum-
marised in Table 5.DISCUSSION
The current study presents consecutive patients with CLI
who underwent de novo IBG at a single vascular centre in
Japan. Many studies including dialysis dependent patients
with CLI have reported medium-term results. In addition,
several reports have focused on patients receiving haemo-
dialysis.10,11 However, these studies had small to moderate
sample sizes. As far as is known, the present study is the
ﬁrst and largest to demonstrate freedom from MALE after
IBG in a haemodialysis only cohort.
In this study, the 30 day mortality after IBG was 9% for pa-
tients receiving haemodialysis. In a meta-analysis, Albers et al.
reported peri-operativemortality of 8.8%.12 Biancari et al. also
reported high peri-operative mortality rates (3e17%).14
Moreover, several studies of EVT showed a mortality rate of
Table 5. Mid-term outcomes and the predictors based on
multivariate analysis.
Clinical outcomes Predictors HR 95% CI p
Amputation free
survival
Non-ambulatory
status
3.04 1.59e5.82 <.01
Freedom from
MALE
Non-ambulatory
status
4.98 1.91e12.96 <.01
Limb salvage Non-ambulatory
status
5.18 1.47e18.30 .01
Survival Non-ambulatory
status
2.35 1.19e4.64 .01
Albumin <3.0 g/dL 2.26 1.12e4.58 .02
Ejection fraction
<40%
2.24 1.05e4.79 .04
Note. HR ¼ hazard ratio; CI ¼ conﬁdence interval; MALE ¼ major
adverse limb events.
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of the present study are comparable with these past ﬁndings.
In addition, this study demonstrates that an independent
predictor of 30 day mortality is an EF <40%. Biancari et al.
demonstrated that diabetes, CAD, foot gangrene, and urgent
operations were also independent predictors of 30 day mor-
tality and/or major lower-limb amputation.14
Several small to moderate sized (n ¼ 20e121) studies of
IBG to treat CLI in patients receiving haemodialysis have
demonstrated 1 and 2 year limb salvage rates of 64e88%
and 56e85%, respectively. Moreover, these studies have
shown that the overall survival rates at 1 and 2 years were
50e78% and 23e45%, respectively.15e20 The results pre-
sented here show that the limb salvage rates were 89% and
85% at 1 and 2 years, respectively, and that survival was
68% and 50% at 1 and 2 years, respectively. These data are
equivalent to those reported in other studies. Recently,
Nakano et al. reported the outcomes of EVT to treat CLI in
Japanese patients on haemodialysis.13 The study showed
that the limb salvage rates at 1 and 3 years were 81% and
77%, respectively, and that the survival rates at 1 and 3
years were 72% and 47%, respectively. The patient proﬁles
and limb selection differed between the cohort of Nakano
et al. and that presented here,13 and the limb salvage rate
in the present study was slightly higher than that of the
cohort of Nakano et al.13 However, neither the study of
Nakano et al. nor the present one evaluated wound healing
time after revascularisation, which might have caused the
difference in limb salvage rates. Several studies have
concluded that endovascular techniques that use a mini-
mally invasive approach should be considered as an alter-
native to bypass grafting.21,22 However, the ﬁnal results of
the BASIL trial demonstrated that the outcomes of bypass
surgery after failed EVT were worse than those of bypass
surgery performed as the ﬁrst line treatment, suggesting
that EVT should not always be the ﬁrst line treatment.5
Recently, a working group under the auspices of the
Society for Vascular Surgery used pooled data from the
PREVENT III, BASIL, and Circulase studies to identify ex-
pected outcomes for vein bypass surgery as the relevant
standard for comparing new devices. This group endorsed a
set of three safety and six efﬁcacy objective performancegoals (OPGs) for CLI based on the pooled data from these
surgical controls.8 The group suggested MALE and AFS,
among others, and reported that the OPGs were AFS,
freedom from MALE, limb salvage, and survival, with rates
of 71%, 71%, 84%, and 80%, respectively. In the present
study, 1 year values for AFS (64%), freedom from MALE
(81%), limb salvage (89%), and survival (68%) were ob-
tained, with poorer AFS and survival than in a study by
Conte.8 However, the three randomised controlled trials
from which the OPGs were derived did not include patients
with CLI receiving haemodialysis. A meta-analysis of the
results of revascularisation using vein grafts revealed that
the 2 year amputation free rate for the lower limb was 75%
and that the survival rate was 54% in patients on dialysis.12
These values were comparable to the medium-term results
of the present study. Conte also suggested using
MALE þ perioperative death (POD) as the primary efﬁcacy
end point for single arm trials for CLI.8 However, patients
receiving haemodialysis are high risk candidates for post-
operative complications and 30 day mortality.14 Therefore,
an attempt was made to identify separately 30 day mor-
tality (POD) and freedom from MALE.
Little information has been available on the predictors of
medium or long-term outcomes in patients receiving hae-
modialysis. In our study, hypoalbuminaemia was one of the
independent risk factors for survival. When performing
infrainguinal revascularisation (including EVT) to treat CLI in
patients receiving haemodialysis, Biancari et al. reported
that hypoalbuminaemia was a predictor of survival.16
Additionally, Azuma et al. studied 228 patients with CLI,
including non-haemodialysis patients, and showed that
hypoalbuminaemia was an independent risk factor for
clinical failure after distal bypass.23 Hypoalbuminaemia is
also associated with poor nutritional status, chronic
inﬂammation, and poor clinical outcomes, including mor-
tality, in patients receiving dialysis.24
In the patients in the present study, the rate of statin use
was only 12%. Statins have certain long-term beneﬁts in
patients with PAD,2 and the pleiotropic effects and cardio-
vascular beneﬁts of statin therapy have been well estab-
lished.25 However, under the Japanese National Health
Insurance system, statins are only permitted to be prescribed
for patients with hyperlipidaemia (low-density lipoprotein
>140 mg/dL, high-density lipoprotein <40 mg/dL, tri-
glycerides >150 mg/dL), and hyperlipidaemia was noted in
only 15% of the patients in the present study. In other
studies, hyperlipidaemia has been reported in 5e23% of
patients.13,16,26
Other reports have shown that myocardial infarction,
congestive heart failure, and CAD are predictors of sur-
vival.27,28 The present study showed that non-ambulatory
status was one of the negative predictors of limb salvage,
AFS, and survival. Goodney et al. also reported that non-
ambulatory status was a negative factor for major ampu-
tation after bypass surgery in patients with CLI and claudi-
cation.29 Several studies have additionally reported on the
predictors of the clinical outcomes of CLI after EVT in the
dialysis population.21,22,30 Kumada et al. reported that
Clinical Outcomes After IBG for CLI 701non-ambulatory status was a predictor not only of survival,
but also of limb salvage after infrapopliteal angioplasty in
patients receiving dialysis.30 This factor was one of the
signiﬁcant risk factors for survival in both the surgical and
the endovascular treatment populations. However, in this
study, EVT was considered as the ﬁrst line therapy for pa-
tients with CLI with both non-ambulatory status and
hypoalbuminaemia because it is safe and less invasive, and
because of its initial clinical success rate.13,30
Because the beneﬁts of surgical revascularisation might
be modest for patients with ESRD, several authors have
recognised a role for primary amputation when tissue loss is
extensive.31 However, the authors of the present study
believe that revascularisation in patients receiving haemo-
dialysis with CLI is necessary whenever feasible for the
maintenance of quality of life. Risk stratiﬁcation should be
performed to improve both the safety and the efﬁcacy of
IBG, and to determine the optimal revascularisation treat-
ment, whether IBG or EVT.
This study has several limitations. Firstly, it was a retro-
spective, single-centre study. Larger multicentre studies are
warranted to corroborate the ﬁndings. Secondly, the
choices of procedure and medications depended on the
surgeon. These choices might have affected clinical out-
comes. Thirdly, wound healing time was not investigated
because not all of the medical charts were recorded pre-
cisely. However, it is still believed that bypass grafting offers
several advantages over EVT and that this comparison is an
important topic for future studies.
CONCLUSION
The pathophysiology of patients with CLI receiving hae-
modialysis can be characterised as follows: (1) Patients
enjoyed satisfactory freedom from MALE and limb salvage,
but survival and AFS were signiﬁcantly less than those re-
ported for IBG in patients with CLI who did not also suffer
from dialysis; (2) patients with an EF <40%, low Alb
(<3.0 mg/dL), or non-ambulatory status have particularly
poor clinical outcomes after IBG.
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